SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

NCT06239480 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Microcystic Lymphatic Malformation

Interventions

DRUG: QTORIN 3.9% Rapamycin Anhydrous Gel

Sponsor

Palvella Therapeutics, Inc.

Collaborators

[object Object]